Reduced Factorial Design, Randomized, Double Blind Trial Comparing Combinations of Telmisartan 20 or 80 mg and Simvastatin 20 or 40 mg With Single Component Therapies in the Treatment of Hypertension and Dyslipidemia

Trial Profile

Reduced Factorial Design, Randomized, Double Blind Trial Comparing Combinations of Telmisartan 20 or 80 mg and Simvastatin 20 or 40 mg With Single Component Therapies in the Treatment of Hypertension and Dyslipidemia

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Simvastatin; Telmisartan
  • Indications Hypercholesterolaemia; Hypertension
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jun 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
    • 23 Jan 2008 The expected completion date for this trial is now 1 Aug 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top